Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma.
Taskinen M, Louhimo R, Koivula S, Chen P, Rantanen V, Holte H, Delabie J, Karjalainen-Lindsberg ML, Björkholm M, Fluge Ø, Pedersen LM, Fjordén K, Jerkeman M, Eriksson M, Hautaniemi S, Leppä S. Taskinen M, et al. Among authors: pedersen lm. PLoS One. 2014 Mar 13;9(3):e91031. doi: 10.1371/journal.pone.0091031. eCollection 2014. PLoS One. 2014. PMID: 24625556 Free PMC article. Clinical Trial.
Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, Pedersen LM, Lauritzsen GF, Ekanger R, Nilsson-Ehle H, Nordström M, Fredén S, Jerkeman M, Eriksson M, Väärt J, Malmer B, Geisler CH. Andersen NS, et al. Among authors: pedersen lb, pedersen lm. J Clin Oncol. 2009 Sep 10;27(26):4365-70. doi: 10.1200/JCO.2008.21.3116. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652064 Clinical Trial.
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB. Green TM, et al. Among authors: pedersen lm. J Clin Oncol. 2012 Oct 1;30(28):3460-7. doi: 10.1200/JCO.2011.41.4342. Epub 2012 Jun 4. J Clin Oncol. 2012. PMID: 22665537
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy.
Riihijärvi S, Nurmi H, Holte H, Björkholm M, Fluge O, Pedersen LM, Rydström K, Jerkeman M, Eriksson M, Leppä S. Riihijärvi S, et al. Among authors: pedersen lm. Eur J Haematol. 2012 Nov;89(5):395-402. doi: 10.1111/ejh.12005. Epub 2012 Sep 14. Eur J Haematol. 2012. PMID: 22882209 Clinical Trial.
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M. Holte H, et al. Among authors: pedersen lm. Ann Oncol. 2013 May;24(5):1385-92. doi: 10.1093/annonc/mds621. Epub 2012 Dec 17. Ann Oncol. 2013. PMID: 23247661 Free article. Clinical Trial.
Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma.
Mylam KJ, El-Galaly TC, Hutchings M, Brown P, Himmelstrup B, Gerke O, Gillstrøm D, Sillesen IB, Munksgaard L, Pedersen BB, Christiansen I, Jensen P, Nielsen AL, Pedersen LM. Mylam KJ, et al. Among authors: pedersen lm, pedersen bb. Leuk Lymphoma. 2014 Jul;55(7):1563-9. doi: 10.3109/10428194.2013.850165. Epub 2013 Nov 14. Leuk Lymphoma. 2014. PMID: 24144339
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D'Amore F, Nilsson-Ehle H, Jensen P, Pedersen M, Geisler CH, Jerkeman M. Abrahamsson A, et al. Among authors: pedersen m, pedersen lm. Blood. 2014 Aug 21;124(8):1288-95. doi: 10.1182/blood-2014-03-559930. Epub 2014 May 23. Blood. 2014. PMID: 24859361 Free article. Clinical Trial.
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.
Mylam KJ, Kostakoglu L, Hutchings M, Coleman M, Lamonica D, Czuczman MS, Diehl LF, Nielsen AL, Jensen P, Loft A, Hendel HW, Iyer V, Leppä S, Jyrkkiö S, Holte H, Eriksson M, Gillstrøm D, Hansen PB, Seppänen M, Hjorthaug K, Brown Pde N, Pedersen LM. Mylam KJ, et al. Among authors: pedersen lm. Leuk Lymphoma. 2015 Jul;56(7):2005-12. doi: 10.3109/10428194.2014.975800. Epub 2014 Nov 20. Leuk Lymphoma. 2015. PMID: 25330442
A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry.
Gang AO, Pedersen M, d'Amore F, Pedersen LM, Jensen BA, Jensen P, Møller MB, Mourits-Andersen HT, Pedersen RS, Klausen TW, de N Brown P. Gang AO, et al. Among authors: pedersen m, pedersen lm, pedersen rs. Leuk Lymphoma. 2015;56(9):2556-62. doi: 10.3109/10428194.2015.1010078. Epub 2015 Feb 17. Leuk Lymphoma. 2015. PMID: 25629994
228 results